Krop IE et al. |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. |
2015 |
Ann. Oncol. |
pmid:25355722
|
Martin M et al. |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
2016 |
Ann. Oncol. |
pmid:27052654
|
Wall ME and Wani MC |
Antineoplastic agents from plants. |
1977 |
Annu. Rev. Pharmacol. Toxicol. |
pmid:326159
|
Maslin DN |
[Ansamycins]. |
1979 |
Antibiotiki |
pmid:37801
|
Mescher C et al. |
Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. |
2017 |
Anticancer Res. |
pmid:28668870
|
Michel LL et al. |
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
2015 |
Anticancer Res. |
pmid:26254411
|
Tanida S et al. |
Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. |
1979 |
Antimicrob. Agents Chemother. |
pmid:475367
|
Hanka LJ and Barnett MS |
Microbiological assays and bioautography of maytansine and its homologues. |
1974 |
Antimicrob. Agents Chemother. |
pmid:15825322
|
Zhao M et al. |
Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. |
2017 |
Appl. Biochem. Biotechnol. |
pmid:27787765
|
Li T et al. |
Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. |
2015 |
Appl. Biochem. Biotechnol. |
pmid:25564203
|